Cenix, Sygnis in research collaboration

Cenix conducts contract research and develops technology for RNA interference (RNAi), miRNA modulation and high content phenotyping to accelerate target discovery, target validation, and the non-clinical development of new drug candidates.

Sygnis is focused on the research and development of its drug candidates and is now concentrating on its pre-clinical Kibra project for the treatment of various forms of dementia.

As per the agreement, to advance the Sygnis’ Kibra project, Cenix will apply its combined technology including high content screening with gene silencing analyses in cultured human cells, to built and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system.

Using such assays, Cenix will conduct target validation to prioritize novel therapeutic drug target candidates, thereby accelerating Sygnis drug development pipeline.

Cenix CEO/CSO Christophe Echeverri said this project continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets.